Qiagen N : Stifel – European Healthcare Summit Infographic

COMMITTED

OUR 2028 STRATEGY	2028
TARGETS
Sharpen focus on growth pillars to sustain	~7%
profitable growth

TO SOLID PROFITABLE GROWTH

June 17, 2024

Drive efficiency and digitization to fuel growth investments and profitability

Ensure disciplined capital allocation for growth and shareholder value

Deliver through accountable, empowered and reinvigorated leadership

Net sales CER CAGR (2024-28)

≥31%

Adj. operating income margin CER (2028)

SHARPEN FOCUS ON GROWTH PILLARS TO SUSTAIN PROFITABLE GROWTH

Product groups

2024-28 net sales

CER CAGR

Growth pillars	2024 net sales	2028 net sales
CER target	CER target

Sample technologies

Diagnostic solutions

PCR

Genomics / NGS

Low- to mid-

single-digit growth

High-single-digit

growth(1)

Low-teens

growth

Low-teens

growth

QIAcuity dPCR

QIAstat-Dx

QIAGEN Digital Insights Sample technologies

QuantiFERON

>$90 mn

>$100 mn

>$110 mn

>$650 mn

>$450 mn

≥$250 mn

≥$200 mn

≥$200 mn

≥$750 mn

≥$600 mn

DRIVE EFFICIENCY AND DIGITIZATION

ENSURE DISCIPLINED CAPITAL ALLOCATION FOR GROWTH AND VALUE

Operational excellence Positioning QIAGEN for stronger profitable growth

Digitization Accelerating growth and efficiency across QIAGEN

At least 250 bps

adj. operating income margin expansion 2024-28

Organic investments

Focused

M&A

Shareholder returns

Targeted investments

into pillars and digitization to fuel profitable business expansion

Value-creating transactions

to enhance portfolio and maintain leadership

At least ~$1 bn of returns

to shareholders planned for 2024-28 (absent M&A)

BPS - Basis points CAGR - Compound annual growth rate CER - Constant exchange rates

(1) Organic growth excl. NeuMoDx

OUR STRATEGY TO DELIVER ABOVE-MARKET GROWTH

Samples	Sample preparation	Detection	Insights
		PCR
Any	Sample
biological	Genomics / NGS
technologies
sample
		Diagnostic solutions

Accelerate growth

QIAcuity dPCR

Digital PCR for research and clinical

Net sales 1 CAGR CER in $ mn

>25%

≥250

• >90

2019 2024 2028

~20%

Growth focus

>3x increase in sales specialists to gain share from qPCR / NGS

Add >100 new assays in key applications (cancer research, etc.)

Add new panels in EU (3)

Market size 2024

$0.5 bn

>15%

market CAGR 2024-28

$2.0 bn

QIAstat-DxSyndromic testing for rapid clinical results

15

>100

≥200

and U.S. (7)

Capture market share building on

~8%

market CAGR 2024-28

2019 2024 2028

>15%

>4,000 cumulative placements

Add new software and build

$0.6 bn

QIAGEN Digital Insights

Bioinformatics to create genomics data insights

82 >110

≥200

commercial reach

Drive investments in AI / new

>10%

market CAGR 2024-28

Build on

proven leadership

Sample technologies DNA / RNA isolation and automation

QuantiFERON Leading blood-basedtechnology for latent TB

2019 2024 2028

~3-4%

548 >650 ≥750

2019 2024 2028

~7%

240 >450 ≥600

2019 2024 2028

technologies for >14 new AI features

Launch QIAsymphony Connect and QIAsprint Connect instruments

Accelerate in cutting-edge areas (liquid biopsy, microbiome, etc.)

Convert remaining 60% of latent TB market to IGRA testing

Expand global customer base with complete automation advantages

$1.2 bn

~2-3% market CAGR 2024-28

$1.5 bn

~4-5% market CAGR 2024-28

WHY INVEST IN QIAGEN

Trusted high-quality	Differentiated portfolio	Specialist sales force	Targeted investments
to enhance and
brand with strong	in fast-growing market	backed by extensive
improve portfolio
customer networks	segments	digital engagement
ecosystems

CAGR - Compound annual growth rate CER - Constant exchange rates